ZYMVOL, the biotech company based in Barcelona, specialized in the design, development and application of molecular modelling software to enzyme discovery and optimization, has released ZYMEVOLVER 2.0., a new improvement of its in silico enzyme engineering software.
The company, a CataloniaBio & HealthTech member, developed this new version, which aims to tackle some of the most common challenges scientists face while conducting enzyme engineering projects. “It represents a significant improvement in our technology. Since the simulations are performed quicker, scientists will have more time to broaden the sequence space exploration (including long-range mutations) and suggest more mutations per round (from 30->90)”, states Ferran Sancho, senior scientist at ZYMBOL. “This also increases the number of hits: with some customers, only long-range mutations have a positive impact on the enzyme activity. With ZYMEVOLVER 2.0, the number of successful projects also rises”.
For ZYMVOL, the release is seen as a natural step towards their continuous effort to advance its state-of-the-art methods. “We are now able to have access to other, risky, not used till now enzymes, and we can face more challenging projects at lower risk”, states Ryoji Takahashi, senior scientist at ZYMBOL.
ZYMEVOLVER was the first software pipeline developed by ZYMVOL at the time of its foundation. The cornerstone of this technology is the combination of bioinformatics with reliable physics-based simulations that model the interactions between the substrate and the enzyme.
Comments